![]() |
||||||||||||||
![]() |
||||||||||||||
|
Welcome to Transmolecular.com TransMolecular, Inc. is a biotechnology company committed to discovering, developing, and commercializing novel, targeted therapies for glioma, metastatic brain tumors, and aggressive cancers with limited treatment options. Our experienced team is dedicated to expediting the research and approval processes necessary to bring promising new treatment options – as well as renewed hope – to millions of patients who need them. In the pages of this website, you will find information about:
|
TransMolecular Presents Imaging and Pharmacokinetic Analysis of 131Iodine-TM601 at Society for Nuclear Medicine Meeting TransMolecular Reports Positive Results from Phase 1 Trial of 131Iodine-TM601 in Metastatic Melanoma TransMolecular Initiates Phase 1 Clinical Trial for Unlabeled TM601 in
Recurrent Malignant Glioma TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at AACR Annual Meeting |
||||||||||||